Atlas Trials

Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab

Clinical trial NCT03212651 · COMPLETED

Trial details

NCT number
NCT03212651
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2017-10-17
Primary completion
2019-07-18
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.